UPDATE : Monday, September 7, 2020
상단여백
Regulator decides to delist Kolon TissueGene
Kolon TissueGene, an affiliate of Kolon Life Science, is on the verge of be...
by Jeong Sae-im  |  2019-08-27 12:15
라인
Pharmaceutical sector’s job growth twice of all industries’ average
The pharmaceutical industry’s employment growth rate was eight times higher...
by Jeong Sae-im  |  2019-08-26 11:39
라인
HLB wins FDA nod for P2 trial on rivoceranib in adenoid cystic carcinoma
HLB said Thursday it has obtained approval from the U.S. Food and Drug Admi...
by Jeong Sae-im  |  2019-08-23 15:02
라인
GenNBio to test transplanting pig’s pancreatic islet into human next year
GenNBio said it would officially enter the market of transplanting organs f...
by Jeong Sae-im  |  2019-08-23 13:53
라인
Medical device makers to fight bias against homemade products
“We want to raise our local market share to 70 percent, global market share...
by Jeong Sae-im  |  2019-08-20 12:50
라인
Medipost’s stem cell therapy, cord blood bank show solid growth
Medipost’s stem cell therapy Cartistem for osteoarthritis and umbilical cor...
by Jeong Sae-im  |  2019-08-16 16:18
라인
Korean firms eyeing on growing orphan drug market
Investigational drugs developed by Korean pharmaceutical companies are incr...
by Jeong Sae-im  |  2019-08-14 14:48
라인
‘Koreans don’t recognize suicidal signals well’
Korean people have a relatively poor understanding of suicidal ideation, co...
by Jeong Sae-im  |  2019-08-13 11:14
라인
‘CPhI Korea thriving on local firms’ zeal for drug export’
Korea Pharmaceutical Traders Association (KPTA) said it would open a large-...
by Jeong Sae-im  |  2019-08-08 14:54
라인
[Reporter’s Notebook] SillaJen should be ashamed of itself
It was an obvious failure of a drug trial, but the drugmaker said it was no...
by Jeong Sae-im  |  2019-08-07 13:59
라인
HLB to seek pre-NDA meeting with FDA for rivoceranib
HLB said it would request for a pre-New Drug Application (NDA) meeting with...
by Jeong Sae-im  |  2019-08-06 15:43
라인
SillaJen remains confident about Pexa-Vec’s value, despite trial failure
SillaJen said Pexa-Vec, an oncolytic viral drug, still had significant pote...
by Jeong Sae-im  |  2019-08-05 14:49
라인
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension
With the likely suspension of SillaJen’s trial on its major anticancer pipe...
by Jeong Sae-im  |  2019-08-05 11:26
라인
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial
Local biotech shares went down altogether on Friday after SillaJen said it ...
by Jeong Sae-im  |  2019-08-02 15:45
라인
Eutilex pipelines are underrated: CEO
Eutilex CEO Kwon Byeong-se said he felt sorry for the recent fall of the co...
by Jeong Sae-im  |  2019-08-01 16:08
라인
Biotech industry group urges Japan to withdraw export curbs
Korea Biotechnology Industry Organization has delivered a written request t...
by Jeong Sae-im  |  2019-07-25 17:09
라인
[Focus] Korean biopharmas eye US Humira market
Samsung Bioepis’s Humira biosimilar has secured entry into the U.S. market....
by Jeong Sae-im  |  2019-07-25 15:02
라인
Korean drugs strong in anti-reflux treatment market
Locally developed drugs are showing robust sales records in gastroesophagea...
by Jeong Sae-im  |  2019-07-22 15:15
라인
MedPacto passes tech assessment, seeks KOSDAQ listing this year
MedPacto, a subsidiary of Theragen Etex, is pushing be listed on the KOSDAQ...
by Jeong Sae-im  |  2019-07-19 17:01
라인
Biopharmaceutical stocks face grim outlook in 2H
Biopharmaceutical stocks remain sluggish in the second half. Stock prices h...
by Jeong Sae-im  |  2019-07-17 14:11
여백
여백
여백
Back to Top